In 2021, data from the phase I CHRYSALIS trial supported the FDA Accelerated Approval of amivantamab, an EGFR–MET bispecific antibody, for the treatment of advanced-stage non-small-cell lung cancer (NSCLC) harbouring non-classical EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy. Now, new data from the phase III PAPILLON trial demonstrate the efficacy of combining amivantamab with first-line chemotherapy.